title: Should ARDS be renamed diffuse alveolar damage?
authors.affiliation: Division of Pulmonary and Critical Care, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA, 02114, USA. tthompson1@partners.org.
authors.forename: B Taylor
authors.initials: BT
authors.lastname: Thompson
authors.affiliation: Reanimation Medicale, Hôpital de la Croix-Rousse, Lyon, France.|IMRB INSERM 955 Eq13 Créteil, Créteil, France.
authors.forename: Claude
authors.initials: C
authors.lastname: Guérin
authors.affiliation: Hospital Universitario de Getafe, CIBER de Enfermedades Respiratorias, Getafe, Spain.
authors.forename: Andrés
authors.initials: A
authors.lastname: Esteban
mesh_terms: D015415:Biomarkers; D001706:Biopsy; D006801:Humans; D011175:Positive-Pressure Respiration; D011650:Pulmonary Alveoli / Q000473:pathology*; D012128:Respiratory Distress Syndrome / Q000401:mortality / Q000473:pathology* / Q000628:therapy
chemical_list: D015415:Biomarkers